Home » NABI STARTS OVER WITH STAPHVAX
NABI STARTS OVER WITH STAPHVAX
Nabi Biopharmaceuticals Inc. said Tuesday it will
restart development of its experimental vaccine for staph infections and will
look for a partner to help it take the drug through new clinical trials. Nabi
halted the development of StaphVAX in November after the vaccine failed in large-scale
clinical studies.
INS
News
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May